WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526932

CAS#: 866927-10-8

Description: IC87201 is a nNOS-PDZ/PSD-95-PDZ inhibitor. IC87201 showed great promise in cellular experiments and animal models of ischemic stroke and pain. IC87201 inhibited the in vitro binding of nNOS with PSD95, without inhibiting nNOS catalytic activity. nNOS-PSD95 interaction is important in maintaining hypersensitivity in acute and chronic pain. Disruption of the nNOS-PSD95 interaction provides a novel approach to obtain selective anti-hyperalgesic compounds.

Chemical Structure

CAS# 866927-10-8

Theoretical Analysis

MedKoo Cat#: 526932
Name: IC87201
CAS#: 866927-10-8
Chemical Formula: C13H10Cl2N4O
Exact Mass: 308.0232
Molecular Weight: 309.15
Elemental Analysis: C, 50.51; H, 3.26; Cl, 22.93; N, 18.12; O, 5.18

Price and Availability

Size Price Availability Quantity
25.0mg USD 250.0 2 Weeks
50.0mg USD 450.0 2 Weeks
100.0mg USD 750.0 2 Weeks
200.0mg USD 1250.0 2 Weeks
500.0mg USD 2250.0 2 Weeks
1.0g USD 3250.0 2 Weeks
2.0g USD 5650.0 2 Weeks
Bulk inquiry

Synonym: IC87201; IC-87201; IC 87201.

IUPAC/Chemical Name: 2-((1H-Benzo[d] [1,2,3]triazol-5-ylamino) methyl)-4,6-dichlorophenol


InChi Code: InChI=1S/C13H10Cl2N4O/c14-8-3-7(13(20)10(15)4-8)6-16-9-1-2-11-12(5-9)18-19-17-11/h1-5,16,20H,6H2,(H,17,18,19)

SMILES Code: OC1=C(Cl)C=C(Cl)C=C1CNC2=CC=C(NN=N3)C3=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 309.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Smith AE, Xu Z, Lai YY, Kulkarni PM, Thakur GA, Hohmann AG, Crystal JD. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. Behav Brain Res. 2016 May 15;305:23-9. doi: 10.1016/j.bbr.2016.02.021. PubMed PMID: 26909849; PubMed Central PMCID: PMC4808404.

2: Bach A, Pedersen SW, Dorr LA, Vallon G, Ripoche I, Ducki S, Lian LY. Biochemical investigations of the mechanism of action of small molecules ZL006 and IC87201 as potential inhibitors of the nNOS-PDZ/PSD-95-PDZ interactions. Sci Rep. 2015 Jul 16;5:12157. doi: 10.1038/srep12157. PubMed PMID: 26177569; PubMed Central PMCID: PMC4503980.

3: Doucet MV, O'Toole E, Connor T, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface protect against glutamate-induced neuronal atrophy in primary cortical neurons. Neuroscience. 2015 Aug 20;301:421-38. doi: 10.1016/j.neuroscience.2015.06.004. PubMed PMID: 26071957.

4: Lee WH, Xu Z, Ashpole NM, Hudmon A, Kulkarni PM, Thakur GA, Lai YY, Hohmann AG. Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesics. Neuropharmacology. 2015 Oct;97:464-75. doi: 10.1016/j.neuropharm.2015.05.038. PubMed PMID: 26071110; PubMed Central PMCID: PMC4539046.

5: Hu W, Guan LS, Dang XB, Ren PY, Zhang YL. Small-molecule inhibitors at the PSD-95/nNOS interface attenuate MPP+-induced neuronal injury through Sirt3 mediated inhibition of mitochondrial dysfunction. Neurochem Int. 2014 Dec;79:57-64. doi: 10.1016/j.neuint.2014.10.005. PubMed PMID: 25452082.

6: Doucet MV, Levine H, Dev KK, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology. 2013 Jul;38(8):1575-84. doi: 10.1038/npp.2013.57. PubMed PMID: 23446451; PubMed Central PMCID: PMC3682152.

7: Florio SK, Loh C, Huang SM, Iwamaye AE, Kitto KF, Fowler KW, Treiberg JA, Hayflick JS, Walker JM, Fairbanks CA, Lai Y. Disruption of nNOS-PSD95 protein-protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents. Br J Pharmacol. 2009 Sep;158(2):494-506. doi: 10.1111/j.1476-5381.2009.00300.x. PubMed PMID: 19732061; PubMed Central PMCID: PMC2757689.


25.0mg / USD 250.0